Pneumonia Flashcards
CURB-65 Criteria. (Harrison’s 19th edition, pp 806)
Confusion Urea > 7mmol/L RR >/= 30 cpm Blood pressure < or = 90/60 Age >/= 65 yo
Pathologic phases of pneumonia. (Harrison’s 19th edition, pp 804)
Edema
Red hepatization
Gray hepatization
Resolution
Most common organism in community-acquired pneumonia. (Harrison’s 19th edition, pp 804)
Streptococcus pneumoniae
Criteria for adequate sputum sample for culture. (Harrison’s 19th edition, pp 806)
> 25 Neutrophils per low-power field
< 10 squamous epithelial cells per low-power field
Most frequently isolated pathogen in blood cultures. (Harrison’s 19th edition, pp 806)
Streptococcus pneumoniae
Most important risk factor for antibiotic-resistant pneumococcal infection. (Harrison’s 19th edition, pp 806)
Use of a specific antibiotic within the previous 3 months
Treatment for outpatients with community-acquired pneumonia who are previously healthy and no antibiotics use in the past 3 months. (Harrison’s 19th edition, pp 808)
Macrolide OR Doxycycline
Clarithromycin 500mg PO BID
Azithromycin 500mg PO x 1 dose then 250mg PO OD
Doxycycline 100mg PO BID
Indication for Chest tube insertion in patients with parapneumonic pleural effusion. (Harrison’s 19th edition, pp 809)
pH < 7
Glucose level < 2.2mmol/L
Lactate dehydrogenase > 1000U/L
(+) bacteria seen or cultured
Most obvious risk factor for Ventillator-associated pneumonia. (Harrison’s 19th edition, pp 810)
Endotracheal tube
Mechanical factors in host defense for pneumonia. (Harrison’s 19th edition, pp 804)
Hairs and turbinates Branching architecture of the tracheobronchial tree Mucociliary clearance Local antibacterial factors Gag reflex Cough mechanism Normal flora
Treatment for outpatients with community-acquired pneumonia who have comorbidities or antibiotics in past 3 months. (Harrison’s 19th edition, pp 808)
Fluroquinolone OR B-Lactam + macrolide Moxifloxacin 400 mg PO OD Gemifloxacin 320mg PO OD Levofloxacin 750mg PO OD Amoxicillin 1gm PO TID Co-amoxiclav 2gm PO BID Ceftriaxone 1-2gm/IV OD Cefpodoxime 200mg PO BID Cefuroxime 500mg PO BID
In pneumonia, the percent yield from blood cultures when samples are collected before antibiotic therapy. (Harrison’s 19th edition, pp 806)
Low (5-14%)
In pneumonia, which Legionella pneumophila serogroup/s can be detect with a legionella antigen test in the urine? (Harrison’s 19th edition, pp 806)
Serogroup 1 only (sensitivity 90%, specificity 99%)
Sensitivity and Specificity for pneumococcal urine antigen test to diagnosed Pneumococcal pneumonia. (Harrison’s 19th edition, pp 806)
sensitivity 80%
specificity >90%
Yield of positive cultures from sputum samples. (Harrison’s 19th edition, pp 806)
Highly variable (< or = 50%, even in cases of proven bacteremic pneumococcal pneumonia)
Access point of microorganisms to the lower respiratory tract. (Harrison’s 19th edition, pp 804)
Aspiration from the oropharynx
Inhaled as contaminated droplets
Hematogenous spread – rarely (from tricuspid endocarditis)
Contiguous extension – rarely (from an infected pleural or mediastinal space)
Most common access (pathophysiology) of pneumonia. (Harrison’s 19th edition, pp 804)
Aspiration from oropharynx
Initial presentation of elderly patients with pneumonia. (Harrison’s 19th edition, pp 805)
New-onset or worsening confusion and few other manifestations
Clinical manifestation of pneumonia if the pleura is involved. (Harrison’s 19th edition, pp 805)
Pleuritic chest pain
Physical findings of patients with pneumonia. (Harrison’s 19th edition, pp 805)
Vary with the degree of pulmonary consolidation and presence/absence of pleural effusion
Increase RR and use of accessory muscles – common
Palpation – increased (consolidation) or decreased (effusion) tactile fremitus
Percussion – dull to flat
Auscultation – Crackles, bronchial breath sounds and pleural friction rub
In pneumonia, gross hemoptysis is suggestive of? (Harrison’s 19th edition, pp 805)
CA-MRSA
Empirical antibiotic treatment of health care-associated pneumonia. (Harrison’s 19th edition, pp 812)
B-lactam + gram neg coverage + gram pos coverage
Ceftazidime 2gm/IV Q8, Cefepime 2gm/IV Q8-12, Piptazo 4.5gm/IV Q6, Imipinem 500/IV Q6 or 1gm/IV Q8, meropenem 1gm/IV Q8
+
Gentamicin or tobramycin 7mg/kg/IV Q24, amikacin 20mg/kg/IV Q24, Ciprofloxacin 400mg/IV Q8, Levofloxacin 750mg/IV Q24
+
Linezolid 600mg/IV Q12
Vancomycin 15mg/kg Q12
Prevention strategies for VAP. (Harrison’s 19th edition, pp 813)
Avoidance of intubation
Decrease duration of MV
Avoidance of prolonged antibiotic courses
Short course of prophylactic antibiotics for comatose patients
Head elevation 30-45O
Prophylactic agents that raise gastric pH
Oropharyngeal and bowel flora decontamination
Tight glycemic control
Microorganisms in CAP that are intrinsically resistant to beta lactam agent. (Harrison’s 19th edition, pp 804)
Atypical organisms